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1. Introduction 
Urologic malignancies, including prostate, bladder, and kidney cancer, have been in the 
forefront in the use of immunotherapies. However, the tight link between inflammation and 
cancer can lead to both pro-tumorigenic and anti-tumorigenic effects. Elucidating the 
crosstalk between immune and cancer cells of the tumor microenvironment will enhance 
our ability to manipulate the immune system towards generation of an anti-tumor response. 
Over the last decade, the discovery of pattern recognition receptors of innate immunity has 
revolutionized the understanding of host-pathogen interactions and shed new light on the 
mechanisms of existing immunotherapies. In this chapter, we will discuss the role of 
inflammation in cancer, highlight the current status of immunotherapies in urologic 
malignancies, review the evolution of pattern recognition receptors, and discuss strategies in 
harnessing pattern recognition receptors to develop novel therapies. 
2. Dual nature of inflammation in cancer  
The initial observation associating leukocytes with tumor cells by Rudolf Virchow in 1863 
marked the link between inflammation and cancer. Since then, inflammation has been 
shown to play distinct roles during tumor initiation, promotion, and metastasis. While 
growing evidence demonstrates the ability of chronic inflammation to initiate tumors, other 
examples support a role of tumor immune surveillance in cancer elimination. Perhaps the 
role of inflammation in cancer is analogous to a balance, with scales on opposite sides 
tightly interdependent. The challenge remains in skewing these inflammatory responses to 
tip the balance towards an anti-tumor response (Figure 1).  
Arguably the cornerstone of anti-tumor immunity rests on the concept of immune 
surveillance, proposed by Sir Macfarlane Burnet and Lewis Thomas in 1957, whereby the 
immune system surveys, recognizes, and eliminates developing tumors. Tumor surveillance 
necessitates recognition of tumor antigens or “altered” self-antigens, and gained acceptance 
as new models emerged in the field of immunology. This included pre-clinical studies 
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demonstrating tumor sensitivity to IFN treatment in vivo and increased carcinogen–
induced tumor formation in perforin-deficient mice (Dighe et al., 1994; Russell and Ley, 
2002). With the development of mice deficient in recombination activating gene 2 (Rag2), a 
gene essential in rearrangement and recombination of immunoglobulins and the T cell 
receptor, more convincing evidence revealed increased spontaneous development of tumors 
(Shankaran et al., 2001). Indeed, immunocompromised humans have increased risks of 
developing cancers including those of the bladder, kidney, colon, lung, non-Hodgkin’s 
lymphoma, and melanoma (Dunn et al., 2002). More recently, the concept of tumor 
surveillance has been modified to incorporate a broader context of immunoediting, which 
not only encompasses the ability to recognize and eliminate tumors, but also suggests that 
immunogenicity of tumors can be shaped during tumor development, requiring constant 
interaction and modulation with the immune system. This was based on studies showing 
that tumors formed in an immunodeficient host were more immunogenic than tumors from 
an immunocompotent host. In these series of experiments, increased rejection of tumors 
generated from Rag2-deficient mice occurred when transplanted into immunocompetent 
hosts, but not Rag2-deficient hosts, while tumors derived from immunocompetent hosts 
grew similarly both in immunocompetent and Rag2-deficient hosts (Shankaran et al., 2001).   
 
 
Fig. 1. Balance of Inflammatory Responses. 
Interestingly, activation of the immune system to treat cancer predates the understanding of 
modern immunology and tumor surveillance. Together with reports since the 17th century 
describing regression of tumors following attacks of erysipelas, the origins of 
immunotherapy stems from the work of Freidrich Fehleisen in the late 1800’s, who 
inoculated patients with sarcoma using the bacteria causing erysipelas, Streptococcus 
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pyogenes. William Coley, the “father of immunotherapy,” began treating cancer patients with 
inoculation combining Streptococcus pyogenes and Serratia marcesens. In many instances, 
injection of the live bacteria induced complete regression of tumors. The use of Coley’s toxin 
continued from 1893 to 1963, largely until the advent of radiotherapy and chemotherapy. In 
1943, isolation of lipopolysaccharide as the active component of Coley’s toxin and more 
recently, identification of Toll-like receptor (TLR) 4 as the receptor for lipopolysaccharide, 
defined the molecular basis for this cancer regression. These findings marked the resurgence 
in the use of pathogens and pathogen-based components in cancer therapy (Rakoff-Nahoum 
and Medzhitov, 2009).  
However, certain types of inflammation can promote deleterious effects. Although the 
typical immune response is self-limiting, persistent activation of the immune system may 
lead to a condition of chronic inflammation (Naugler et al., 2007). Loss of epithelial barrier 
function with resulting tissue destruction allows the entrance of pathogens and the 
recruitment of inflammatory cells and mediators. Combined with the persistence of 
inflammatory signals and the absence of factors that normally mediate resolution of the 
acute response, it is postulated that chronic inflammation ensues. Chronic inflammation 
defines many human conditions including chronic gastritis, hepatitis, and atherosclerosis. 
An epidemiologic association exists between several inflammatory diseases and an 
increased risk for malignant transformation. Furthermore, infection with a specific pathogen 
predisposes to the inflammatory disease, suggesting a causative link from pathogen to 
chronic inflammation to the initiation of cancer. The most clearly defined example is 
infection with Helicobacter pylori resulting in chronic gastritis, peptic ulcer disease, and 
ultimately gastric carcinoma. In addition, this association is found in the development of 
hepatitis, cirrhosis, and hepatocellular carcinoma following infection by the hepatitis B and 
C viruses, in Burkitt’s lymphoma in parts of Africa and nasopharyngeal carcinoma in 
Southeast Asia with Epstein Barr virus, and in the development of cervical carcinoma 
following infection with certain types of the human papilloma virus. However, the majority 
of individuals infected with these pathogens do not develop clinical disease, much less the 
corresponding cancer.   
In later stages of cancer, solid malignancies can develop necrotic centers as they outgrow 
their blood supply, releasing inflammatory mediators such as IL-1 and intracellular 
components such as heat shock proteins and high-mobility group protein B1 (HMG-B1) 
(Vakkila and Lotze, 2004). These factors activate recruitment of inflammatory cells such as 
tumor associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs) that 
facilitate angiogenesis to sustain tumor growth, leading to a cascade of cytokines and 
chemokines such as TGF. In some instances, these inflammatory responses may influence 
epithelial-to-mesenchymal transition and development of tumor invasion and metastases, 
while in others, inflammation associated with radiation or chemotherapy may augment anti-
tumor immunity (Ghiringhelli et al., 2009; Grivennikov et al., 2010).   
The dichotomy between anti- and pro-tumor inflammation may be dictated by the type, 
location, and timing of the inflammatory response. This may elucidate why certain patients 
respond to immunotherapy and others do not. Dissecting the composition of the cells within 
the tumor microenvironment, the cytokines and chemokines involved in autocrine and 
paracrine signaling cascades, and understanding its molecular mechanisms will be central in 
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understanding the paradigm on how inflammation influences tumorigenesis. The discovery 
of Toll-like receptors has provided insight into a molecular basis for antigen recognition and 
modulation of innate and adaptive immunity, but as you will see, has only widened the 
dualistic understanding of inflammation and cancer.  
3. Components of the tumor microenvironment  
The tumor microenvironment consists of a complex milieu of stromal and inflammatory 
cells, soluble factors, and extracellular matrix, intertwined with tumor cells. Identifying and 
understanding the regulation of the tumor microenvironment will be critical in designing 
therapies to inhibit tumor growth and invasion.  
3.1 Stroma 
The stromal components of the tumor microenvironment include fibroblasts, endothelial 
cells, and pericytes. Cancer associated fibroblasts (CAFs) provide growth factors, 
chemokines, and metalloproteinases essential for cellular communication during cancer 
proliferation and invasion (Bhowmick et al., 2004; Sato et al., 2009). Endothelial cells and 
pericytes deliver nutrients and oxygen to the cancer cells, allowing their continued growth 
and survival. The stromal cells along with the extracellular matrix present not only a 
physical barrier for tumor invasion and metastases, but also a lymphatic and vascular 
barrier to cancer-specific antibodies preventing immunoconjugates from reaching tumor 
cells (Yasunaga et al., 2011).  
3.2 Inflammatory cells 
Tumor-associated macrophages (TAMs) constitute the majority of infiltrating cells in the 
microenvironment (Jinushi et al., 2011). TAMs are classified into M1 and M2 types similar to 
Th1 and Th2 CD4+ T cells, with M1 macrophages favoring pathogen elimination and M2 
macrophages associated with angiogenesis and tissue remodeling (Balkwill and Mantovani, 
2001). The most potent of antigen-presenting cells, dentritic cells (DCs), process and present 
antigens on their surface in context with major histocompatibilty complex class I (MHC) and 
class II molecules, to interact with CD8+ T lymphocytes and CD4+ T helper cells respectively. 
These are divided into myeloid DCs and plasmacytoid DCs, characterized by production of 
type I interferons. Natural killer cells (NKs) of innate immunity eradicate cells by inducing 
cytotoxicity through the release of perforin and granzyme that target the cell to destruction 
by apoptosis, while NKT cells share similarities with T cells, with recognition of lipid and 
glycolipid antigens. A subset of early myeloid cells termed myeloid derived suppressor cells 
(MDSCs) has the ability to suppress NK, NKT, and T cell responses, marked by production 
of L-arginine and upregulation of nitric oxide synthase 2 (Dolcetti et al., 2008).  
Tumor infiltrating lymphocytes (TILs) represent the adaptive arm of immunity and include 
cytotoxic CD8+ T cells (CTLs), B lymphocytes, and CD4+ T helper cells, including Th1, Th2, 
and Th17 cells typically associated with autoimmunity. T regulatory (Treg) cells, 
characterized by the expression of the forkhead box P3 transcription factor (Foxp3), along 
with MDSCs, may play an important role in immune tolerance, regulating the 
immunosuppressive environment of cancer and posing as a barrier to successful 
immunotherapy.   
www.intechopen.com
Immunotherapy in Urologic Malignancies:  
The Evolution and Future of Pattern Recognition Receptors 5 
3.3 Cytokines and chemokines 
Cytokines and chemokines provide autocrine and paracrine signaling and play a critical role 
in shaping the tumor microenvironment. These include cytokines that favor development of 
anti-tumor immunity include IL-12, IFN, and IFN and those that enhance immune 
suppression such as IL-10, IL-17, and TGF or tumor progression such as IL-1 or IL6 
(Grivennikov et al., 2010). Chemokines of the CC and CXC family secreted by tumors and 
infiltrating leukocytes, recruit inflammatory cells to the tumor microenvironment. This 
network of cytokines and chemokines plays an active role in regulating communication 
between the tumor, stroma, and inflammatory cells. Together, they have shown to influence 
tumor survival, growth, and epithelial-to-mesenchymal transition (EMT).   
4. Immunotherapy in urologic malignancies  
The incidence of urologic malignancies with bladder, kidney, and prostate cancer comprise 
almost 40% of cancer in men and almost 23% of all cancers in the United States, according to 
statistics provided by the 2010 American Cancer Society. Remarkably, in each of these 
malignancies, a Food and Drug Administration (FDA) approved immunotherapy exists 
(Figure 2). The following section briefly discusses the approved therapies and the strategies 
utilized.  
 
  
 
Fig. 2. Use of Immunotherapies in Bladder, Kidney, and Prostate Cancer.  
______
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4.1 Bladder cancer 
Bladder cancer incidence ranks the 4th and 9th most prevalent in men and women, 
respectively, in the United States. Since its first therapeutic instillation in the bladder by Jean 
B. deKernion in 1975 for melanoma and later by Alvaro Morales for urothelial cancer, 
intravescical instillation of bacillus calmette-guerin (BCG), an attenuated strain of 
Mycobacterium bovis, has demonstrated to be more effective than chemotherapy and is the 
standard intravesical treatment for non-muscle invasive bladder cancer and carcinoma in 
situ, garnering FDA approval in 1990. In the landmark trial, BCG administration in nine 
patients with a history of recurrent urothelial carcinomas reduced recurrences from a pre-
treatment rate of 22 recurrences amongst the nine patients within 77 months, to just one 
during 41 months following therapy (Morales et al., 1976). BCG immunotherapy induces a 
local inflammatory response recruiting macrophages, DCs, T cells, NK cells, and neutrophils 
(Saint et al., 2001). Elevated cytokines including IL-6, IL-10, IL-12, IFN┛, and TNF┙ have 
been reported in patients following intravesical BCG (de Reijke et al., 1996). BCG can bind 
fibronectin on urothelial cells and more recently has been shown to mediate its effector 
functions through activation of TLR2 and TLR4 (Rakoff-Nahoum and Medzhitov, 2009; 
Ratliff, 1991; Tsuji et al., 2000).   
BCG treatment can lead to significant morbidity including debilitating arthritis or sepsis. 
Efforts to increase its efficacy and decrease toxicity led to co-administration of BCG with 
IFN┙, first recognized as an effective intravesical treatment in 1988 (Torti et al., 1988). Pre-
clinical studies established a synergy between BCG and IFN┙, with clinical trials 
demonstrating efficacy and safety using combinatorial administration of low-dose BCG and 
IFN-2b with improved side effect profiles (Bazarbashi et al., 2011; Stricker et al., 1996; Torti 
et al., 1988). Currently, this combination has been used in BCG refractory patients with an 
additional 25% response rate (Gallagher et al., 2008).   
4.2 Kidney cancer 
As the 7th and 8th leading site of new cancer cases in men and women in the United States 
respectively, renal cell carcinoma (RCC) is relatively resistant to chemotherapy and 
radiotherapy. Reports of spontaneous regression following cytoreductive nephrectomy 
suggested an immunological basis of disease initiated from the primary tumor. The use 
of cytokine therapy has made important impacts in its treatment. This includes high dose 
IL-2, which garnered FDA approval in 1992 for metastatic RCC following a review of 225 
patients in seven phase II trails, with complete responses occurring in 10%-20% of 
patients (Fyfe et al., 1995). IFN, although currently not FDA approved for this 
indication, has shown efficacy for melanoma as well as for metastatic RCC. A landmark 
trial on the benefits of nephrectomy in 120 metastatic RCC patients undergoing IFN -2b 
therapy revealed that IFN with cytoreductive nephrectomy resulted in a median 
survival of 11.1 months over IFN alone with a median survival of 8.1 months (Flanigan 
et al., 2001). IL-2 is a potent T cell activator, while IFN induces T cell activation, 
upregulates MHC class I and II, and augments NK cells. In the age of targeted therapies 
to various tyrosine kinases, cytokine therapy remains the only curative therapy for 
metastatic RCC.  
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4.3 Prostate cancer 
Prostate cancer remains the leading incidence of cancer in men, and the second highest 
cause of cancer death in men in the United States. Following hormone ablation for 
metastatic disease, patients inevitably develop castrate-resistant prostate cancer (CRPC), 
with options limited to systemic chemotherapy. The approval of the first in class cell-based 
vaccine for prostate cancer in 2010, sipuleucel-T, ended the search for an immunological 
treatment for prostate cancer that began decades earlier. Sipuleucel T combines ex vivo 
patient-derived DCs with a fusion of the tumor antigen prostatic-acid phosphatase and GM-
CSF. In a phase III trial on 127 men with CRPC, median survival of those treated with 
sipuleucel-T was 25.9 months compared to 21.4 months for placebo, with generation of PAP-
specific T cell immunity (Small et al., 2006).   
5. Inflammation in urologic malignancies  
An emerging theme in cancer is how the inflammatory composition of the tumor 
microenvironment influences cancer prognosis and overall patient survival. This has been 
demonstrated in breast cancer, where the ratio of CD68+ macrophages to CD8+ T cells, CD4+ 
to CD8+ T cells, or Th2 to Th1 CD4+ T cells have all independently correlated with survival 
(Kohrt et al., 2005). In colon cancer, infiltration of CD8+ T cells, CD45RO, and Foxp3+ Tregs 
predicts overall survival better than grade and stage (Galon et al., 2006; Salama et al., 2009).  
In human bladder cancer patients, elevated numbers of CD8+ T cells in TILs have predicted 
greater disease-free and overall survival (Sharma et al., 2007). However, negative regulators 
have been linked with more aggressive cancers, including CD4+CD25+Foxp3+ Tregs and 
cytokines important in their development such as TGF (Loskog et al., 2007). These 
suppressive effects may lead to T cell anergy and ineffective cytotoxic responses, 
questioning the functionality of infiltrating CD8+ T cells. A similar observation exists in 
kidney and prostate cancer. In advanced renal cell carcinoma patients, elevated levels of 
Tregs are present in peripheral blood, with IFN treatment resulting in inhibition of both 
CD4+ T lymphocytes and Tregs (Tatsugami et al., 2010). Increased circulating CD4+ and 
CD8+ Tregs have been linked in human prostate cancer, while a murine model 
demonstrated tolerization of CD8+ T cells (Anderson et al., 2007; Kiniwa et al., 2007; Miller et 
al., 2006; Sfanos et al., 2008).   
The balance in TILs towards a suppressive state suggests a major role of antigen tolerance in 
tumorigenesis. Current strategies aimed at targeting these negative regulatory populations 
include monoclonal antibody therapies against the CD28 family of co-receptors CTLA-4 or 
PD-1, with an anti-CTLA-4 monoclonal antibody ipilimumab recently approved by the FDA 
in 2011 (Mangsbo et al., 2010; May et al., 2011). The signals that program the composition of 
the tumor microenvironment and the ability to alter individual components to favor a cell-
mediated anti-tumor immunity will be an important future direction.  
6. Pattern recognition receptors  
Charles Janeway first proposed the idea of germline-encoded pattern recognition receptors 
(PRRs) of innate immunity that recognized conserved motifs of microbial origin termed 
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pathogen-associated molecular patterns (PAMPs). These evolutionarily conserved receptors 
found throughout the animal kingdom activate the innate arm of immunity as well as direct 
adaptive immunity. Humans and microbes exist in direct interaction. In an environment 
with constant exposure to microbes, the host immune system is challenged to discern 
between benign flora and potential pathogens, and to initiate an appropriate immune 
response. The innate immune response initiated immediately upon pathogen entry mediates 
components such as macrophages, neutrophils, NK cells, alternative complement proteins, 
and other anti-microbial molecules. Recognition of pathogens in innate immunity utilizes 
germ line-encoded proteins, without the generation of lasting immunity. In addition to 
phagocytosis and killing of pathogens, innate immune cells synthesize and secrete a broad 
range of inflammatory mediators and cytokines that regulate systemic responses to 
infection, recruit additional white blood cells to sites of inflammation, and importantly, 
dictate the nature of the adaptive response. In contrast, the adaptive response, mediated by 
lymphocytes and their effector functions, requires several days to develop. Adaptive 
immunity has the ability to generate antigen-specific receptors in T cell receptors and 
immunoglobulins through somatic cell DNA rearrangement, and to elicit lasting immunity 
through development of memory cells.   
The PRR superfamily now includes the family of Toll-like receptors (TLRs), cytosolic NOD-
like receptors (NLRs) and RIG-I-like receptors, and membrane-bound C-type lectin 
receptors (CLRs) (Elinav et al., 2011; Kawai and Akira, 2011). In addition to host defense, 
PRRs may also play a major role in tissue repair and maintenance of tissue homeostasis, and 
emerging evidence suggests a role in cancer. In the following section, we will discuss the 
most well characterized family of Toll-like receptors and their role in tumor surveillance and 
cancer therapy.  
6.1 Toll-like receptors signaling 
TLRs are best defined in their host defense role through their ability to recognize PAMPs, 
leading to enhanced uptake of microorganisms, generation of reactive oxygen and nitrogen 
intermediates, and recruitment of leukocytes to the area of inflammation (Kawai and Akira, 
2011; Modlin and Cheng, 2004). TLRs also shape the induction of adaptive immunity 
through activation of APCs by upregulation of co-stimulatory molecules CD80 and CD86. 
Currently, 10 human and 12 murine TLRs have been identified with PAMPs ranging from 
lipopolysaccharide (LPS) found in gram-negative bacterial walls recognized by TLR4, 
peptidoglycan and lipoprotein from gram-positive bacteria specific to TLR2 in conjunction 
with TLR1 or TLR6, double stranded RNA produced by many viruses for TLR3, single 
stranded RNA by TLR7 and TLR8, unmethylated CpG motifs with TLR9, and flagellin for 
TLR5 (Table 1). More recently, endogenous ligands termed danger-associated molecular 
patterns (DAMPs), including heat-shock proteins, the chromatin component HMG-B1, 
surfactant, protein A, fibronectin, heparan sulfate, fibrinogen, hyaluronan, and other 
components of injured cells, have also been identified suggesting a role for this receptor 
family in inflammatory responses resulting from tissue damage, such as lung injury or 
ischemic-reperfusion injury, or during tumor growth and necrosis (Rakoff-Nahoum and 
Medzhitov, 2009).   
TLRs contain multiple leucine-rich repeats in the extracellular domain, and an intracellular 
Toll/IL-1R/Resistance (TIR) domain conserved in all TLRs (Kawai and Akira, 2011). 
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Proximally, the TIR interacts with other TIR domain adaptor proteins including recruitment 
of myeloid differentiation factor 88 (MyD88) and TIR domain-containing adaptor protein 
(TIRAP/Mal), which initiate a signaling cascade to the serine kinase IL-1R-associated kinase 
(IRAK) to tumor necrosis factor (TNF)-receptor-associated factor 6 (TRAF6), activating 
transforming growth factor--activated protein kinase 1 (TAK1). This results in activation of 
downstream transcription factors including NF-B, MAP kinases, Jun N-terminal kinases, 
p38, ERK, and interferon regulator factors (Modlin and Cheng, 2004).   
 
Toll-like receptor   
TLR-1  
 
TLR-2  
 
 
TLR-3  
 
TLR-4  
 
 
TLR-5  
 
TLR-6  
 
TLR-7  
 
TLR-8  
 
TLR-9  
 
TLR-10  
 
TLR-11 
Ligand(s)  
Lipoprotein - bacteria  
 
Lipoprotein - bacteria; Heat-shock protein 70 -
endogenous  
 
Double-stranded RNA - virus  
 
Lipopolysaccharide - gram-negative bacteria;  
Heat-shock protein 60/70 - endogenous  
 
Flagellin - bacteria   
 
Lipoprotein - bacteria   
 
Single-strand RNA - virus   
 
Single-strand RNA - virus   
 
CpG-containing DNA - bacteria and virus   
 
Unknown   
 
Urogenic bacteria 
Localization   
Membrane  
 
Membrane  
 
 
Endosome   
 
Membrane  
 
 
Membrane  
 
Membrane  
 
Endosome   
 
Endosome   
 
Endosome   
 
Membrane  
 
Membrane 
Table 1. Human Toll-like Receptors and Known Ligands (So and Ouchi, 2010).  
Although most TLRs utilize the MyD88 pathway, TLR3 and TLR4 interact with the adaptor 
protein TIR-domain-containing adapter-inducing interferon-┚ (TRIF) also known as Toll-
like receptor adaptor molecule 1 (TICAM-1) to activate a MyD88-independent pathway 
leading to IRF3 activation and production of type I interferons. TLR3 has been implicated in 
NK cell activation, and while MyD88-dependent pathways largely regulate CTL induction, 
NK activation requires MyD88-independent pathways (Akazawa et al., 2007; Alexopoulou 
et al., 2001; Guerra et al., 2008).  
6.2 Toll-like receptors in activation and regulation of inflammatory responses 
Predominantly expressed on innate immune cells such as macrophages, DCs, and 
plasmacytoid DCs, recognition of PAMPS by TLRs leads to activation of transcription 
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factors leading to production of inflammatory target genes such as cell cycle regulator genes 
c-myc and cyclin D1, cell survival genes bcl-xL, angiogenesis factors including VEGF, 
inflammatory cytokines such as IL-1, IL-6, and IL-8, type I interferons, chemokines, and T 
cell co-stimulatory molecules. These signals are crucial elements in the coordination of the 
host innate immune responses leading to recruitment of neutrophils, natural killer cells, and 
induction of antimicrobial peptides, resulting in killing of pathogens. Activation of TLRs 
ultimately dictate the nature of adaptive responses through dendritic cell maturation and 
the development of CTLs (Modlin and Cheng, 2004).   
While stimulation of TLRs induces robust inflammatory pathways, negative regulatory 
mechanisms exist to balance immune activation to prevent chronic inflammation and 
autoimmunity. This includes decoy receptors, intracellular or transmembrane regulators, 
control of TLR expression, or caspase-dependent apoptosis of TLR-expressing cells 
(Kobayashi et al., 2002; Liew et al., 2005; Liu and Zhao, 2007). Activation of suppressor 
pathways through induction of cytokines IL-10, IL-27, and cells such as Tregs or MDSCs, 
may pose a significant barrier in antigen tolerance during tumor surveillance, reflected by 
increased numbers of suppressor cells in cancer patients (van Maren et al., 2008). Several 
lines of evidence support a critical role of TLRs in manipulating these suppressor cell 
populations. Multiple TLRs, including TLR2, TLR4, and TLR8 are expressed on the surface 
of Tregs, and may have a direct regulatory role with suppression of human prostate tumor 
infiltrating CD8+ Treg cells following activation of TLR8 (Liu and Zhao, 2007). TLR9 
activation has been shown to inhibit Tregs through IL-6 produced by DCs, although reports 
also show a TLR9-mediated induction of IL-10 and thus activation of Tregs (Jarnicki et al., 
2008; Pasare and Medzhitov, 2003). In an autochthonous prostate cancer model, TLR3 
activation increased infiltration of tumor infiltrating T and NK cells, and suppressed splenic 
Tregs, suggesting the ability of TLR activation to selectively modify the tumor 
microenvironment (Chin et al., 2010). The relationship between TLRs and MDSCs is less 
clear, but a recent study showed that TLR9 activation may inhibit MDSCs in a murine model 
(Ostrand-Rosenberg and Sinha, 2009; Peng et al., 2005; Zoglmeier et al., 2011). Collectively, 
these studies suggest that selective activation of TLRs may not only increase tumor 
infiltration of cytotoxic T and NK cells, but may also inhibit specific types of suppressor 
populations.  
6.3 Toll-like receptors on tumor cells 
In addition to immune cells, a broad variety of epithelial cells including colon, ovarian, 
bladder, kidney, and prostate express various TLRs. Although the endogenous role of TLRs 
on epithelial cells is unclear, it may stem from regulation of tissue growth and repair. 
Activation of TLRs in various tumor lines and models has shown both evidence of tumor 
reduction and cancer progression (Maruyama et al., 2011). In prostate and kidney cancer cell 
lines, TLR3 activation has been shown to induce apoptosis, while TLR9 has been shown to 
promote prostate cancer invasion, and IL-8 and TGF production in vitro (Di et al., 2009; 
Ilvesaro et al., 2007; Paone et al., 2008; Taura et al., 2010). In bladder cancer lines, elevated 
expression of TLR2-4, 5, 7, and 9 was detected in non-muscle invasive tumors, with 
decreased expression in muscle invasive tumors (Ayari et al., 2011).   
The role of TLRs on epithelial cells needs to be clarified. What is the impact of TLR 
expression on epithelial cells during tumor initiation, growth, and response to 
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immunotherapies? In human population studies, a sequence variant in a 3’-untranslated 
region of TLR4 as well as polymorphisms in the TLR gene cluster encoding TLR1, 6 and 10, 
and the downstream signaling mediator IRAK1 and IRAK4 confer increased prostate cancer 
risk (Lindstrom et al., 2010). However, the contribution of these TLR signaling components 
is unclear. In order to distinguish the role of TLRs on epithelial cells versus stromal or 
immune cells, tissue specific models will need to be examined.   
6.4 Toll-like receptors in immune surveillance 
The evidence of TLRs in mediating immune surveillance is based on tumor growth in 
knockout models of TLRs and their signaling adaptors, with studies supporting tumor 
promoting as well as suppressing effects. Exogenous administration of TLR ligands may not 
truly demonstrate a role of tumor surveillance and may enhance host immunity above 
physiologic levels. In support of a role of TLRs in tumor surveillance, mice deficient in TLR3 
and TLR9 show increased growth of subcutaneously implanted prostate cancer, while 
deficiency in the negative regulatory adaptor molecule IRAK-M impairs growth of 
implanted tumor cells (Chin et al., 2010; Xie et al., 2007). Supporting a role in tumorigenesis, 
MyD88 mediates tumor initiation in a mouse model of spontaneous intestinal tumorigenesis 
and diethylnitrosamine-induced hepatocellular tumors (Naugler et al., 2007; Rakoff-
Nahoum and Medzhitov, 2007; Xie et al., 2007). These opposing effects are confounded by 
the tumor origin, tumor model used, and potential contribution of TLRs on tumor cells, and 
further studies will need to explore this important issue.  
7. Toll-like receptors in human immunotherapy  
The role of TLRs in cancer therapy harnesses the exogenous use of synthetic TLR agonists to 
enhance host immunity. Despite pre-clinical evidence supporting anti-tumor responses as 
well as facilitating tumor promotion, the use of TLR agonists have a significant clinical 
importance and a promising future. Most clinical trial designs focus on the adjuvant 
properties of TLRs, predominantly by stimulating APCs through upregulation of co-
stimulatory molecules such as CD80 and CD86 (Medzhitov et al., 1997). In addition to 
activation of adaptive immunity, effector functions include increase recruitment of innate 
immune cells such as NK, NKT, T cells, modulating the cytokine milieu, and direct 
cytotoxicity of tumor cells (Figure 3). Overcoming immune suppression is a major obstacle 
for successful immunotherapy and TLR activation may suppress Tregs and MDSCs to break 
antigen tolerance in conjunction with activation of adaptive immunity (Pasare and 
Medzhitov, 2003). More recently, strategies have adopted the use of TLR agonists with 
tumor antigens for the development of cancer vaccines.   
Freund’s complete adjuvant (FCA) has been the most common adjuvant for antibody 
production, produced in a water-in-oil emulsion containing heat-killed mycobacterial cells 
(Stewart-Tull, 1996). TLR2 and TLR4 play a crucial role in the recognition of FCA, which has 
increased antibody responses crucial for delayed-type hypersensitivity reactions over 
Freund’s incomplete adjuvant lacking mycobacteria (Azuma and Seya, 2001). BCG has been 
used for over three decades as intravesical therapy in bladder cancer and mediates its 
function through TLR2 and 4 pathways as well. Recent trials utilizing components of 
mycobacterial cell walls rather than live bacteria may have similar efficacy while reducing 
toxicity (Chin et al., 1996). In fact, activation of TLRs using synthetic PAMPs reduces tumor 
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growth in pre-clinical models in bladder and prostate cancer. With the impact of IFN in 
kidney cancer patients, it is likely that TLR activation may play an important role in kidney 
cancer in particular with TLRs that activate type I interferons such as TLR3.  
  
Fig. 3. The Direct and Indirect Influences of Pattern Recognition Receptors on Tumor 
Growth.  
Although many TLRs share common signaling pathways, it is evident that ligation of 
different TLRs will induce unique gene expression profiles that translate to specific effector 
functions (Doyle et al., 2002). As supported by the wide variation in pre-clinical responses, 
the effector functions and resulting tumor response by TLR activation may change based on 
tumor type, location, dose, and timing. In the near future, perhaps activation of specific 
TLRs can be tailored to augment a desired tissue-specific effector function that partners with 
a particular vaccine.   
To date, three TLR agonists have been used in clinical trials, all recognizing nucleic acids for 
receptors expressed on endosomal membrances. The only approved agonist, the single-
stranded RNA analogue imiquimod specific for TLR7, showed activity in murine colon 
cancer and sarcoma models, inducing IFN and IL-12 to activate CTLs and myeloid DCs 
(Maruyama et al., 2011). Initially used clinically for actinic keratosis and genital warts, 
imiquimod has show activity against superficial basal cell carcinoma and received FDA 
approval in 2004.   
Unmethylated CpG oligodeoxynucleotides (ODN) found in bacterial and viral DNA has 
been used in phase I-III trials against multiple malignancies including kidney, breast, 
melanoma, and lymphomas (Krieg, 2008). Ligands for TLR9 have been grouped into three 
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different classes based on their roles in activating the immune system. A-class CpG ODN 
(CpG-A) stimulate type I interferon production by plasmacytoid dendritic cells, activating 
natural killer cells and IFN (Krug et al., 2001); B-Class CpG ODNs (CpG-B) induce B cell 
and monocyte maturation, leading to B cell proliferation with little pDC activation; and C-
Class CpG ODNs (CpG-C) mediate signaling pathways of both CpG-A and CpG-B 
(Rothenfusser et al., 2004). Although pre-clinical trials demonstrate that TLR9 activation 
potently induces Th1 responses, NK activation, stimulation of cytokines TNF┙, IL-12, and 
IFN┛, and induces a strong CD8+ T-cell response, clinical trials have not yielded robust 
results (Valmori et al., 2003). This may be in part due to different expression of TLR9 in 
murine models with broad expression in myeloid DCs, plasmacytoid DCs, macrophages, 
and B cells, with expression limited to pDCs and B cells in humans.   
To address this disparity, combinatorial strategies attempt to enhance the activity of CpG 
ODN, with the addition of alum, emulsigen, and polyphosphazenes (Malyala et al., 2009). 
Other strategies include inhibition of p38 that may enhance T cell activation or through 
blockade of CTLA-4 or PD-1 (Mangsbo et al., 2010; Takauji et al., 2002). These combinatorial 
strategies will be increasingly important in promoting synergic responses to augment host 
immunity, while unhinging negative regulatory factors.   
TLR3 ligand polyriboinosinic:polyribocytidylic acid (poly(I:C)), a synthetic analog of 
double-stranded RNA, has demonstrated to be a promising adjuvant for immunotherapy. 
Studies have reported poly(I:C) as an effective inducer of inflammatory cytokines, dendritic 
cells, and macrophages, leading to subsequent activation of natural killer cells. While 
poly(I:C) has proven effective in inhibiting tumor metastasis and prolonging survival in 
animal models, the drawback exists in its inability to efficiently penetrate the cell membrane 
in order to bind to its cognate receptor. The development of stabilized compounds, 
including polyICLC, has been used in phase II studies against gliomas (Butowski et al., 
2009). A recent phase I trial against multiple malignancies including advanced bladder cancer 
utilized a novel vaccine approach combining a human chorionic gonadotropin- antigen 
fusion protein with adjuvants poly ICLC and the TLR7/8 agonist resiquimod (Morse et al., 
2011). This orchestration of TLR-based adjuvant activation with tumor antigen stimulation is 
promising and utilizes the ability of TLRs for cross antigen presentation, allowing extracellular 
antigens to be processed and presented by class I MHC (Oh and Kedl, 2010).   
8. Therapeutic design and conclusion  
Urologic malignancies comprise 23% of all cancers in the United States, excluding basal skin 
cancer. Immunotherapeutic approaches in urologic malignancies broadly encompass 
cytokine-based, bacteria-mediated, and cell-based vaccine therapies. This demonstrates the 
immunological sensitivity of urologic malignancies and opens avenues to develop novel 
strategies. Clearly the composition of inflammation in the tumor microenvironment 
influences tumor growth, metastases, and overall survival. Toll-like receptors play 
important roles in host defense against pathogens, and tissue homeostasis and repair in 
response to tissue damage. Mounting evidence suggests that TLRs can recognize 
endogenous antigens released from tumors and mediate tumor immune surveillance. 
Furthermore, exogenous activation of TLRs can alter the tumor microenvironment and 
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induce adaptive immunity, influencing the response not only to immunotherapies, but also 
potentially to radiation, chemotherapy, and targeted therapies.  
Understanding the specificities of various TLRs will be critical, as will be determining the 
timing of agonist stimulation, dose, and tissue specificity. Exploring the potential of other 
PRR families in cancer is clearly an open field. Similarly, challenges in modulating 
immunity to prevent antigen tolerance or an inappropriate response will need to be 
addressed. By incorporating activation of distinct PRR and PRR signaling pathways, 
specific components of the tumor microenvironment may be modulated to augment cell-
mediated immunity. Combining the ability of PRRs to regulate suppressor cells, novel 
vaccine strategies may overcome antigen tolerance. At the same time, caution needs to be 
exercised to understand direct PRR effects on tumors and development of pro-
tumorigenic immunity.  
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